← Back to all trials
Terminated
NCT05914467
TDM-optimized Teicoplanin Dosing Versus Standard of Care
Conditions: Bacterial Infections
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE4
Enrollment: 54
Sponsor: Radboud University Medical Center
Location: RadboudUMC Nijmegen
Summary
Value of TDM for teicoplanin is not well defined. In this single-center low-interventional randomized trial the investigators aim to investigate the superiority of teicoplanin TDM-optimized using Model-Informed-Precision-Dosing (MIPD) of unbound concentrations versus the standard of care (dosing based on antibiotic guidelines) in target attainment.
Eligibility Criteria
Inclusion Criteria:
1. The patient is admitted to the ICU, haematology, gastroenterology or orthopaedics department.
2. The patient is at least 18 years old on the day of inclusion.
3. The patient is treated with teicoplanin as part of standard care.
4. The patient or a representative is willing to sign the Informed Consent Form
Exclusion Criteria:
1. The patient has previously participated in this study.
2. The patient receives any form of renal replacement criteria (RRT) other than CVVHD / CVVHDF.
3. Expected duration of teicoplanin therapy is less than 5 days.
4. The patient is pregnant
Source: ClinicalTrials.gov (NCT05914467). StuddyBuddy aggregates publicly available trial information.
